Gubra A/S Holds First Shareholder and Analyst Call to Present 2030 Strategy

Gubra A/S held its first shareholder and analyst call on October 27, 2026, with CEO Markus Rohrwild presenting the company's 2030 strategy. The Danish biotech outlined plans to scale its research and development engine and expand its clinical-stage pipeline, according to Seeking Alpha.

Gubra's First Capital Markets Event

Head of Investor Relations Adam Lange opened the call by welcoming attendees in person and virtually to what he called Gubra's first-ever capital markets event of this type. Lange said the company had issued a press release that morning outlining key messages to be discussed during the presentations.

"Today is, of course, a great opportunity for Gubra to share more about the company, our pipeline and the ambitions for the years ahead," Lange said. He noted that the presentations would cover the company's 2030 strategy and include forward-looking statements subject to risks and uncertainties.

Rohrwild walked through Gubra's strategy and ambitions toward 2030, according to the agenda Lange described. Chief Science Officer Louise Dalboge, Chief Medical and Development Officer Thomas Langenickel, Head of Gubra Ventures & BD Zoe Johnson, Head of Gubra CRO Trine Hamann and Chief Financial Officer Kristian Borbos were listed as company participants.

Gubra's Revenue and Partnership Record

Gubra is a Danish publicly listed biotech that combines AI-driven peptide drug discovery through its streaMLine platform with preclinical CRO services, according to akta.pro company records. The company serves 17 of the 20 largest global pharmaceutical companies through proprietary disease models and partnered development programs in obesity and metabolic disease, the same records show.

Gubra reported revenue of DKK 2,637 million in 2025, reflecting its landmark license agreement with AbbVie, other biotech activities and CRO business revenue. The company posted a record-breaking net profit of DKK 1,700 million in Q4 2025, driven primarily by the upfront payment from the AbbVie outlicensing deal. Gubra had 300 employees as of early 2026, having doubled from previous levels.

Gubra's Path to the 2030 Plan

On October 27, 2026, Borsen reported that Gubra will accelerate its research and development to increase the number of drug candidates in its pipeline. TradingView reported the same day that the 2030 strategy highlights four clinical assets and two partnered Phase 2 obesity programs.

In September 2026, Borsen reported that Rohrwild plans to build a sales force to create a commercial future for the biotech company. He said Gubra could consider becoming a commercial entity in a few years but that it is too early now as he needs a pipeline in place.

In August 2026, Borsen reported that AbbVie had begun a new trial with Gubra's experimental weight-loss drug and that Gubra would receive a payment of 320 million kroner.

Gubra's Next Steps

Gubra's 2030 strategy targets a larger clinical-stage pipeline and expanded R&D capacity. The company's own announcement accompanied the October 27 event.